Compare NVEC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVEC | REPL |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 518.0M | 454.6M |
| IPO Year | 1995 | 2018 |
| Metric | NVEC | REPL |
|---|---|---|
| Price | $100.89 | $15.50 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | 130.2K | ★ 5.6M |
| Earning Date | 05-06-2026 | 05-21-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | ★ 0.96 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $26,331,218.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $81.12 | ★ N/A |
| Revenue Growth | ★ 1.76 | N/A |
| 52 Week Low | $57.21 | $1.50 |
| 52 Week High | $135.00 | $16.15 |
| Indicator | NVEC | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 42.09 | 61.95 |
| Support Level | $78.89 | $8.79 |
| Resistance Level | $111.64 | $15.71 |
| Average True Range (ATR) | 5.29 | 0.94 |
| MACD | -2.19 | 0.02 |
| Stochastic Oscillator | 2.41 | 78.31 |
NVE Corp is engaged in developing and selling devices that use spintronics, a nanotechnology that relies on electron spin rather than electron charge to acquire, store, and transmit information. It manufactures high-performance spintronic products including sensors and couplers that are used to acquire and transmit data. The company's products include Digital sensors, Medical sensors, Rotation Sensors, GT Sensors, Angle Sensors, Analog sensors, MSOP Isolators, Passive-In Transceivers, and others. The company manufactures high-performance spintronic products including sensors and couplers. The company's designs are based on giant magnetoresistance GMR and tunneling magnetoresistance TMR combined with integrated circuitry.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.